PureTech Health plc announced that to oversee the LYT-100 development program in IPF, Paul Ford, M.D., Ph.D., has joined PureTech as SVP of Clinical Development. He has built and advanced programs from early to late-stage development at companies including Novartis, Galapagos and Galecto, and he has driven the recruitment and randomization of nearly 1,500 patients with IPF across several clinical studies.